A potential therapeutic strategy for malignant mesothelioma with gene medicine.

Publisher: Hindawi Pub. Co Country of Publication: United States NLM ID: 101600173 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2314-6141 (Electronic) NLM ISO Abbreviation: Biomed Res Int Subsets: MEDLINE

Original Publication: New York, NY : Hindawi Pub. Co.

Adenoviridae* ; Gene Expression* ; Genetic Vectors* ; Transgenes*; Lung Neoplasms/*therapy ; Mesothelioma/*therapy; Animals ; Asbestos/adverse effects ; Carcinogens/toxicity ; Genetic Therapy ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Mesothelioma/genetics ; Mesothelioma/pathology ; Mesothelioma, Malignant ; Neoplasm Metastasis

Malignant mesothelioma, closely linked with occupational asbestos exposure, is relatively rare in the frequency, but the patient numbers are going to increase in the next few decades all over the world. The current treatment modalities are not effective in terms of the overall survival and the quality of life. Mesothelioma mainly develops in the thoracic cavity and infrequently metastasizes to extrapleural organs. A local treatment can thereby be beneficial to the patients, and gene therapy with an intrapleural administration of vectors is one of the potential therapeutics. Preclinical studies demonstrated the efficacy of gene medicine for mesothelioma, and clinical trials with adenovirus vectors showed the safety of an intrapleural injection and a possible involvement of antitumor immune responses. Nevertheless, low transduction efficiency remains the main hurdle that hinders further clinical applications. Moreover, rapid generation of antivector antibody also inhibits transgene expressions. In this paper, we review the current status of preclinical and clinical gene therapy for malignant mesothelioma and discuss potential clinical directions of gene medicine in terms of a combinatory use with anticancer agents and with immunotherapy.

Endocrinology. 2006 Feb;147(2):754-61. (PMID: 16254028)
Nat Clin Pract Oncol. 2008 Mar;5(3):136-47. (PMID: 18227828)
Oncogene. 2010 Feb 25;29(8):1145-54. (PMID: 19935710)
Nat Genet. 2011 Aug 28;43(10):1022-5. (PMID: 21874000)
J Thorac Oncol. 2006 Sep;1(7):701-11. (PMID: 17409940)
Mol Ther. 2010 Oct;18(10):1874-84. (PMID: 20664527)
Lung Cancer. 2012 Sep;77(3):567-71. (PMID: 22770372)
J Gene Med. 2006 Oct;8(10):1232-42. (PMID: 16900558)
Mol Ther. 2010 Apr;18(4):852-60. (PMID: 20068553)
Cancer Sci. 2003 Apr;94(4):321-7. (PMID: 12824898)
J Thorac Oncol. 2008 Jul;3(7):756-63. (PMID: 18594322)
J Clin Oncol. 2007 Jun 10;25(17):2406-13. (PMID: 17557954)
Mol Ther. 2007 Nov;15(11):1982-90. (PMID: 17653103)
Cancer. 2007 Apr 15;109(8):1454-61. (PMID: 17348013)
Cancer. 2007 Mar 1;109(5):933-8. (PMID: 17279584)
Cancer Gene Ther. 2012 Feb;19(2):126-34. (PMID: 22095385)
Cancer Res. 2006 Oct 1;66(19):9736-43. (PMID: 17018633)
Cancer Res. 2012 Apr 1;72(7):1621-31. (PMID: 22323527)
Clin Cancer Res. 2006 Sep 1;12(17):5224-30. (PMID: 16951242)
Oncol Res. 2008;17(6):239-46. (PMID: 19192718)
J Natl Cancer Inst. 2000 Apr 19;92(8):636-41. (PMID: 10772681)
Cancer Res. 2009 Oct 1;69(19):7713-20. (PMID: 19773437)
N Engl J Med. 2005 Oct 13;353(15):1591-603. (PMID: 16221782)
Mol Ther. 2011 Jan;19(1):140-9. (PMID: 20978474)
Cancer Gene Ther. 2011 Aug;18(8):571-8. (PMID: 21660062)
J Clin Oncol. 2009 Jun 20;27(18):3007-13. (PMID: 19364962)
Int J Cancer. 2010 Oct 15;127(8):1948-57. (PMID: 20104519)
Mol Ther. 2010 May;18(5):903-11. (PMID: 20179683)
Cancer Biol Ther. 2011 Nov 15;12(10):888-95. (PMID: 22024742)
J Clin Oncol. 2003 Jul 15;21(14):2636-44. (PMID: 12860938)
J Clin Oncol. 2005 Oct 1;23(28):6881-9. (PMID: 16192580)
BMC Cancer. 2010 Feb 22;10:54. (PMID: 20175889)
Anticancer Res. 2003 Jan-Feb;23(1A):33-8. (PMID: 12680192)
J Gene Med. 2011 Jun;13(6):353-61. (PMID: 21674738)
Lung Cancer. 2009 May;64(2):140-7. (PMID: 18835652)
Cancer Treat Rev. 2010 Feb;36(1):24-32. (PMID: 19879055)
J Natl Cancer Inst. 2006 Oct 18;98(20):1482-93. (PMID: 17047197)
Cancer Gene Ther. 2000 May;7(5):663-70. (PMID: 10830713)
Cancer Gene Ther. 2012 Feb;19(2):118-25. (PMID: 22076042)
Cancer Lett. 2009 Nov 18;285(1):89-98. (PMID: 19481338)
Cancer Gene Ther. 2010 Aug;17(8):550-8. (PMID: 20379224)
J Clin Oncol. 2012 May 1;30(13):1541-9. (PMID: 22412141)
Br J Cancer. 2011 Apr 12;104(8):1325-33. (PMID: 21448170)
J Biol Chem. 2009 Aug 14;284(33):22491-22499. (PMID: 19553700)
Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4456-66. (PMID: 17671130)
Cancer Res. 2001 Aug 15;61(16):5959-63. (PMID: 11507034)
Cancer Gene Ther. 2012 Mar;19(3):218-28. (PMID: 22223137)
J Thorac Oncol. 2012 Dec;7(12):1850-1857. (PMID: 23154556)
Mol Ther. 2012 Jan;20(1):221-9. (PMID: 22044933)
Ann Thorac Cardiovasc Surg. 2010 Dec;16(6):389-93. (PMID: 21263418)
J Gene Med. 2006 May;8(5):603-15. (PMID: 16475242)
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1395-9. (PMID: 21642245)
J Gene Med. 2010 Aug;12(8):681-92. (PMID: 20635326)
Hum Gene Ther. 1998 May 1;9(7):1083-92. (PMID: 9607419)
Front Biosci (Landmark Ed). 2011 Jan 01;16:740-8. (PMID: 21196199)
Lancet. 2005 Jul 30-Aug 5;366(9483):397-408. (PMID: 16054941)
Cancer Gene Ther. 2000 Nov;7(11):1421-5. (PMID: 11129284)
Hum Gene Ther. 2006 Nov;17(11):1152-60. (PMID: 17032151)

0 (Carcinogens)
1332-21-4 (Asbestos)

Date Created: 20130314 Date Completed: 20130903 Latest Revision: 20211021

20240829

PMC3581274

10.1155/2013/572609

23484132